Cipla Q1 FY26 results due today; analysts anticipate 10% drop in US revenue, here’s why

Cipla Q1 FY26 Results Preview: Mumbai-headquartered drug maker Cipla is set to report its financial results for the April-June period on Friday, July 25. Analysts expect the pharmaceuticals company to stage a mixed financial performance for the first three months of FY26, with a 10 per cent decline in the company’s US revenue. In FY25, the North American market contributed 28.7 per cent to the company’s revenue.

Cipla Q1 FY26 Results Preview: What to expect in top-line and bottom line?

Cipla is estimated to register a consolidated net profit of Rs 1,174 crore for the quarter ended June 30, marginally below its net profit of Rs 1,177.6 crore a year ago, according to Zee Business research. Its revenue is pegged at Rs 6,970 crore, which translates to a year-on-year increase of 4.1 per cent. 

In FY25, the domesitc market accounted for 42.2 per cent of the company’s total revenue, according to a filing. 

How can investors expect Cipla to perform operationally in Q1 FY26?

Cipla is expected to report Rs 1,672 crore in its June-quarter earnings before interest, taxes, depreciation and amortisation (EBITDA), a decline of 2.5 per cent, according to the research. 

The analysts peg the drug maker’s quarterly margin at 23.99 per cent, 164 basis points (bps) lower from the year-ago period.

Key things to watch out for in Cipla Q1 earnings

According to Zee Business research, investors can expect the following in the pharma company’s upcoming earnings report: 

• A 9.0 per cent increase in domestic revenue owing to a low base
• Up to 10 per cent fall in US revenue, owing to price erosion in G Revlimid and limited approvals on new medicine
• Commentary on the following will be a key monitorable: 
  • An update on the company’s Indore facility
  • An update about the launch of Nilotinib capsules

Cipla shares vs Nifty 50 

In late morning deals, Cipla shares traded mildly higher at Rs 1,488 apiece. The headline Nifty50 index hovered just below the 24,850 mark, down 0.9 per cent for the day. 

At the current level, Cipla shares are down about 2.9 per cent in 2025 so far, in line with a 3.7 per cent decline in the Nifty Pharma but underperforming a 4.6 per cent rise in the Nifty50.